Please assess the completion status of the following clinical trial:

Trial Title: The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Statin treatment for at least 3 weeks~* Reduced HDL: \< 40 mg/dL (1.03 mmol/L) in men or \< 50 mg/dL (1.29 mmol/L) in women~* Plus TWO of the following (thereby defining the patients to have metabolic syndrome (Grundy et al.; Circulation 2005)):~* Elevated waist circumference: ≥ 102 cm (≥ 40 inches) in men or ≥ 88 cm (≥ 35 inches) in women~* Elevated triglycerides: ≥ 150 mg/dL (1.7 mmol/L~* Elevated blood pressure: ≥ 130 mmHg systolic blood pressure or ≥ 80 mmHg diastolic blood pressure or anti-hypertensive treatment~* Elevated fasting glucose: ≥ 100 mg/dL or on drug treatment for elevated fasting glucose~Exclusion Criteria:~* Hypersensitivity to niacin~* Active liver disease or impaired liver function~* Persistent elevation of transaminases~* Cholestasis~* Gastric ulcer~* Acute coronary syndrome~* Gout~* Pregnancy, lactation~* Active infections~* Cancer~* Untreated concomitant diseases~* Renal insufficiency or renal failure~* Hypothyreosis~* Alcoholism~* Myopathies~* Muscle pain under therapy with fibrates or statins~* Hereditary muscle diseases in family history

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Extended-release Niacin
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).